Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct;23(10):2006-2007.
doi: 10.1038/s41436-021-01228-4. Epub 2021 Jun 14.

Correspondence on "Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)" by Ferreira et al

Affiliations
Free article
Comment

Correspondence on "Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)" by Ferreira et al

Rachel Stern et al. Genet Med. 2021 Oct.
Free article
No abstract available

PubMed Disclaimer

Comment in

  • Response to Stern et al.
    Ziegler SG, Ferreira CR. Ziegler SG, et al. Genet Med. 2021 Oct;23(10):2008. doi: 10.1038/s41436-021-01229-3. Epub 2021 Jun 16. Genet Med. 2021. PMID: 34135486 Free PMC article. No abstract available.

Comment on

References

    1. Ferreira, C. R. et al. Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI). Genet. Med. 23, 396–407 (2021). - DOI
    1. Carpenter, T. O. et al. Burosumab therapy in children with X-linked hypophosphatemia. N. Engl. J. Med. 378, 1987–1998 (2018). - DOI
    1. Boyce, A. M., Gafni, R. I. & Ferreira, C. R. Generalized arterial calcification of infancy: new insights, controversies, and approach to management. Curr. Osteoporos. Rep. 18, 232–241 (2020). - DOI
    1. Rutsch, F. et al. Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ. Cardiovasc. Genet. 1, 133–140 (2008). - DOI
    1. Imel, E. A. et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 393, 2416–2427 (2019). - DOI

Substances

Supplementary concepts

LinkOut - more resources